A novel approach to identify candidate prognostic factors for hepatitis C treatment response integrating clinical and viral genetic data
{{output}}
The combined therapy of pegylated interferon (IFN) plus ribavirin (RBV) has been for a long time the standard treatment for patients infected with hepatitis C virus (HCV). In the case of genotype 1, only 38%-48% of patients have a positive response to the comb... ...
